Danyelza Market Report 2026

Danyelza Market Overview

• The Danyelza market growth in the historic period has been driven by poor outcomes in relapsed neuroblastoma, advances in monoclonal antibody therapy • Market expansion is supported by growth in pediatric cancer trials, expansion of immuno oncology pipelines • Growth Driver: Market Growth Driven By Increasing Pediatric Cancer Cases • Market Trend: Targeted Immunotherapy For Neuroblastoma And Beyond • North America was the largest region in 2025.

What Is Covered Under Danyelza Market?

Danyelza, known as naxitamab, is a monoclonal antibody drug combined with granulocyte-macrophage colony-stimulating factor (GM-CSF) to treat certain high-risk cancers. It is primarily approved for pediatric patients aged 1 year and older and adults with relapsed or refractory high-risk neuroblastoma affecting the bone or bone marrow, particularly in cases where prior treatments achieved only partial or stable responses. Danyelza targets GD2, commonly found in neuroblastoma cells, enabling the immune system to attack these cancerous cells effectively. The main types of indications in danyelza are neuroblastoma, osteosarcoma, and other GD2-positive cancers. Neuroblastoma is a type of cancer that develops in nerve cells, commonly affecting children, and danyelza, which is used for treating neuroblastoma, is growing as more therapies are approved for pediatric cancers. The treatment types, which include monotherapy, combination therapy, and end users, are categorized into hospitals, specialty clinics, and cancer and radiation therapy centers.

What Is The Danyelza Market Growth Forecast?

The growth in the forecast period can be attributed to growth in pediatric cancer trials, expansion of immuno oncology pipelines, increased access to specialty cancer centers, supportive reimbursement policies, rising awareness of rare cancers. Major trends in the forecast period include growing adoption of targeted immunotherapy, rising use of gd2 directed treatments, expansion of pediatric oncology therapies, increased combination cancer treatment approaches, focus on refractory and relapsed cancers.

What Is The Driver Of The Danyelza Market?

The increasing prevalence of pediatric cancers is expected to propel the growth of the danyelza market going forward. Pediatric cancers refer to cancers that occur in children and adolescents, including various types such as leukemia, brain tumors, neuroblastoma, and lymphomas. The increasing prevalence of pediatric cancers can be attributed to factors such as advances in diagnostic techniques, environmental exposures, genetic predispositions, and the long-term effects of cancer treatments. Danyelza (naxitamab) is a targeted immunotherapy that helps reduce the prevalence of pediatric cancers by effectively treating high-risk neuroblastoma. Its use in combination with other therapies has shown improved survival rates and reduced disease progression in children with this aggressive cancer. For instance, in October 2024, according to the Cancer Council, an Australia-based non-profit organization, in 2022, around 93 children aged 0-14 years in Australia died from cancer. Further, there were 206 cancer diagnoses in children under 15 and 263 in those aged 15-24 in Victoria. By 2023, there were 6,197 males and 5,523 females alive who had been diagnosed with cancer during childhood or adolescence. Therefore, the increasing prevalence of pediatric cancers is driving the growth of the danyelza industry.

Key Players In The Global Danyelza Market

Major companies operating in the danyelza market are Y-mAbs Therapeutics Inc.

Global Danyelza Market Trends and Insights

Major companies operating in the danyelza market are focusing on developing innovative formulations, such as targeted immunotherapy, to enhance therapeutic options and improve patient outcomes. Targeted immunotherapy refers to treatments that utilize substances to specifically target and attack cancer cells by focusing on proteins or markers, such as GD2 in neuroblastoma, thereby enabling the immune system to destroy malignant cells. For instance, in May 2023, Y-mAbs Therapeutics Inc., a US-based biotech company, received marketing authorization from Brazil's Agência Nacional de Vigilância Sanitária for Danyelza (naxitamab-gqgk) 40 mg/10 mL injection, a treatment for high-risk neuroblastoma. Danyelza is a recombinant humanized monoclonal antibody targeting GD2, a ganglioside prevalent in neuroectoderm-derived tumors and sarcomas, and was developed by Memorial Sloan Kettering Cancer Center under an exclusive license to Y-mAbs.

What Are Latest Mergers And Acquisitions In The Danyelza Market?

In November 2024, Nobelpharma Co., Ltd., a Japan-based pharmaceutical company that develops curative drugs and medical devices, partnered with Y-mAbs Therapeutics Inc. Under the agreement, Nobelpharma will handle the development, regulatory submission, and marketing of DANYELZA in Japan, including sales and distribution, if approved. Y-mAbs Therapeutics Inc. is a US-based biotech company specializing in cancer immunotherapies, including DANYELZA.

What Defines the Danyelza Market?

The danyelza market consists of sales of genetically modified donor pancreas cells, cell transplantation, and immune suppression drugs. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Danyelza Market Report 2026?

The danyelza market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the danyelza industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.